Welcome to our dedicated page for Alnylam Pharmaceuticals SEC filings (Ticker: ALNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alnylam Pharmaceuticals, Inc. (ALNY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on financial performance, capital structure, governance, and material events for a Nasdaq‑listed biopharmaceutical issuer focused on RNA interference (RNAi) therapeutics.
Investors can review current reports on Form 8‑K, where Alnylam reports quarterly financial results, material financing transactions, and other significant developments. Recent 8‑K filings describe quarterly results for periods in 2025, including discussions of net product revenues from AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, collaboration and royalty revenues, and the use of non‑GAAP financial measures. Other 8‑K filings outline a revolving credit facility, convertible senior note offerings, and partial repurchases of existing convertible notes, giving insight into the company’s liquidity and leverage.
Filings also cover governance and compensation matters, such as changes to the Board of Directors and updates to executive roles and compensation in connection with organizational changes in research and development. These disclosures help readers understand how Alnylam structures its leadership and aligns incentives as it advances its pipeline and commercial portfolio.
Through Stock Titan, users can track ALNY’s SEC submissions as they are made available on EDGAR and use AI‑powered summaries to interpret complex sections of lengthy filings. This includes identifying key points in quarterly and annual reports, highlighting notable items in 8‑Ks, and surfacing information about direct financial obligations, credit agreements, and other events that may affect the company’s risk profile. The filings page is a resource for analyzing how Alnylam reports on its RNAi business, capital markets activity, and corporate governance over time.
Alnylam Pharmaceuticals CSO & EVP, Head of Research Kevin Joseph Fitzgerald reported open-market sales of company stock. On March 4–5, 2026, he sold a total of 1,291 shares of common stock in multiple transactions at prices generally in the low $320 range.
Footnotes state that some shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum tax withholding on vested restricted stock units, and that the transactions were made under a Rule 10b5-1(c) trading plan adopted on August 14, 2025. After these sales, Fitzgerald directly owns 20,569 common shares and indirectly holds 537 shares through a managed account associated with the company’s 401(k) matching program.
ALNY reports a Rule 144 notice to sell 658 RSUs slated on 03/03/2026. The filing also lists three reported sales by Kevin Fitzgerald: 01/13/2026 (2290 shares, $848,062.57), 02/17/2026 (2041 shares, $677,531.58), and 03/03/2026 (1652 shares, $528,187.85).
ALNY affiliate filed a Form 144 disclosing a proposed sale of 2,404 common shares arising from restricted stock units dated 03/03/2026. The filing also reports prior sales by Pushkal Garg of 4,627 shares on 02/27/2026 for $1,533,106.94 and 1,775 shares on 03/03/2026 for $567,544.89.
ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief financial officer Jeffrey V. Poulton reported a mix of equity awards and stock sales. He received a stock option for 10,480 shares and 4,769 restricted stock units, both granted on March 2, 2026. The RSUs vest in three equal annual installments over three years, and the option vests over four years with 25% after one year and the balance quarterly thereafter, in each case subject to continued service. On the same date, he sold 2,206 shares of common stock in a series of open‑market transactions at weighted average prices in the low‑ to mid‑$320s per share, pursuant to a mandatory sell‑to‑cover provision to satisfy minimum tax withholding. Following these transactions, he directly held 64,273 common shares and indirectly held 57 shares through a managed account.
ALNY’s EVP and Chief R&D officer Pushkal Garg reported a mix of stock sales and equity awards. On March 2, 2026, he received a stock option for 10,480 shares and 4,769 restricted stock units under Alnylam’s 2018 Stock Incentive Plan, with both awards vesting over time based on continued service.
On March 2 and 3, 2026, he conducted open-market sales totaling 3,492 common shares at prices generally in the $316–$332 range, some under a Rule 10b5-1 trading plan and some automatically sold to cover tax withholding on the equity awards. Footnotes also show 431 shares held via a 401(k) managed account and 250 shares held in a trust for which he disclaims beneficial ownership.
ALNYLAM PHARMACEUTICALS, INC. chief scientific officer Kevin Joseph Fitzgerald reported a mix of stock sales and equity awards. On March 2, 2026, he received a grant of 8,105 stock options and 3,688 shares of common stock represented by restricted stock units that vest in thirds over three years, subject to continued service. The stock options vest over four years, with 25% after one year and the balance in quarterly installments.
Across March 2–3, 2026, he executed open‑market sales totaling 3,250 common shares, some under a mandatory sell‑to‑cover tax provision and under a Rule 10b5‑1 trading plan adopted on August 14, 2025. After these transactions, he directly held 21,860 common shares, 8,105 options, and indirectly held 537 shares through a managed account.
ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief commercial officer Tolga Tanguler reported a mix of equity awards and related share sales. On March 2, 2026, he received stock options for 10,480 shares and a grant of 4,769 shares of common stock represented by restricted stock units that vest over three years.
On the same date, a total of 1,598 shares of common stock were sold in multiple open-market transactions at reported weighted-average prices in the low $320s to low $330s per share. According to the disclosure, these sales were automatically executed under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding obligations. Following these transactions, Tanguler directly owned 36,606 shares of Alnylam common stock.
ALNYLAM PHARMACEUTICALS, INC. executive Bryan Supran, EVP, CLO and Secretary, reported equity awards consisting of stock options and restricted stock units. He received stock options for 3,381 shares at an exercise price of $0.00 per share, and a grant of 1,539 shares of common stock represented by restricted stock units.
The RSUs vest over three years, with one third vesting on each of the first, second and third anniversaries of the grant date, conditioned on continued service. The stock options vest 25% on the first anniversary of the grant date, with the remainder vesting in equal quarterly installments until the fourth anniversary, also subject to continuous service.
ALNYLAM PHARMACEUTICALS, INC. reported multiple equity transactions for Chief Executive Officer Yvonne Greenstreet. She received a grant of 30,425 stock options and 110,746 stock price performance stock units, both at a price of $0.00 per share. She also acquired 13,844 shares of common stock, including restricted stock units under the 2018 Stock Incentive Plan that vest over three years and shares acquired through the company’s 401(k) matching program. On the same date, a total of 6,799 shares of common stock were sold in a series of market transactions at weighted average prices around $323–$333 per share, which the company indicates were automatically sold to cover minimum statutory tax withholding obligations on the awards. Following these transactions, she directly held 98,628 shares of common stock and maintained additional indirect ownership through a managed account, and the performance units may vest on December 31, 2029 depending on future stock price performance.
Alnylam Pharmaceuticals reported that its board granted a special, fully performance-based equity award to CEO Yvonne Greenstreet under the 2018 Stock Incentive Plan. The award targets 55,373 performance share units, with a face value of $18.0 million based on the $325.07 share price on the grant date.
The units can vest only if the company’s stock achieves demanding average price hurdles between $500 and $800 over a 30‑day period before December 31, 2029, allowing 50% to 200% of target shares to vest. If the stock does not reach $500, the award is forfeited. Continued service is generally required, with modified treatment for certain terminations and change in control events.